Take a look at slide #16 of Amarin's presentation. Our 18 to 21% RRR is actually well ahead of many other cardiovascular disease drugs. I know this is not an apples to apples comparison...but take it for what it is.
https://investor.amarincorp.com/static-files/6eca1aa8-cf50-4d4d-a181-a5202f6942cc